Overall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis - Top-Institutions - MDSpire

Overall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis

  • By

  • Johannes Wach

  • Martin Vychopen

  • Alim Emre Basaran

  • Marcos Tatagiba

  • Roland Goldbrunner

  • Erdem Güresir

  • January 9, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    St. Jude Children's Research Hospital
    St. Jude Children's Research Hospital

    Memphis, TN

    Key Differentiators

    • Pediatric Neuro-Oncology
    • Neurosurgery
    • Molecular Genetics

  • #2

    Dana-Farber/Boston Children's Cancer and Blood Disorders Center
    Dana-Farber/Boston Children's Cancer and Blood Disorders Center

    Boston, MA

    Key Differentiators

    • Pediatric Neuro-Oncology
    • Neurosurgery
    • Genomic Medicine

  • #3

    Children's Hospital of Philadelphia (CHOP)
    Children's Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Neuro-Oncology
    • Neurosurgery
    • Translational Research

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Neuro-Oncology
    • Pediatric Oncology
    • Molecular Pathology

  • #5

    University of California, San Francisco (UCSF) Benioff Children's Hospital
    University of California, San Francisco (UCSF) Benioff Children's Hospital

    San Francisco, CA

    Key Differentiators

    • Pediatric Neuro-Oncology
    • Neurosurgery
    • Genomic Medicine

Original Source(s)

Overall survival and progression-free survival in pediatric meningiomas: a systematic review and individual patient-level meta-analysis

  • by Johannes Wach, Martin Vychopen, Alim Emre Basaran, Marcos Tatagiba, Roland Goldbrunner, Erdem Güresir

  • January 9, 2025

Related Content

Immune biomarker landscape and fusion partner–phenotype associations in thoracic and head-and-neck NUT carcinoma

Biotech exec Jeremy Levin on the industry’s strategic turning point

Management of toxicities from antibody – drug conjugates in breast cancer